insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification.

증례보고 1/5 보강
Internal medicine (Tokyo, Japan) 2025 Vol.64(23) p. 3460-3464
Retraction 확인
출처
PubMed DOI PMC

Tanaka T, Makimoto G, Sumii R, Omote R, Ando Y, Ninomiya K, Ichihara E, Ohashi K, Maeda Y, Tabata M

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

This case report describes a 70-year-old female with cancer of unknown primary origin (CUP) who exhibited multiple distant lymph node metastases.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Tanaka T, Makimoto G, et al. (2025). Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification.. Internal medicine (Tokyo, Japan), 64(23), 3460-3464. https://doi.org/10.2169/internalmedicine.5028-24
MLA Tanaka T, et al.. "Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification.." Internal medicine (Tokyo, Japan), vol. 64, no. 23, 2025, pp. 3460-3464.
PMID 40399079
DOI 10.2169/internalmedicine.5028-24

Abstract

This case report describes a 70-year-old female with cancer of unknown primary origin (CUP) who exhibited multiple distant lymph node metastases. Despite conventional chemotherapy (carboplatin and paclitaxel) and immunotherapy (nivolumab), disease progression was noted. Genomic profiling revealed MET amplification, leading to the administration of capmatinib, a selective MET tyrosine kinase inhibitor. The patient experienced substantial tumor reduction with dose adjustments due to adverse effects, indicating the potential efficacy of capmatinib in treating CUP with MET amplification.

MeSH Terms

Humans; Female; Aged; Neoplasms, Unknown Primary; Proto-Oncogene Proteins c-met; Gene Amplification; Treatment Outcome; Imidazoles; Protein Kinase Inhibitors; Lymphatic Metastasis; Benzamides; Triazines

같은 제1저자의 인용 많은 논문 (5)